Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,165 total articles
Todd M. DuChene, Core Scientific's Chief Legal and Administrative Officer, sold 10,000 shares of the company's common stock on April 1, 2026, generating $152,523. The transaction followed a March 31, 2026 vesting of performance-based restricted stock units and tax-withholding related to that vesting. The company has also expanded its funded commitm…
Grid Dynamics Holdings Inc. (GDYN) Chief Operating Officer Yury Gryzlov sold 1,245 shares on April 2, 2026, under a Rule 10b5-1 plan, netting $6,897. The transaction was disclosed on a Form 4 filing with the SEC. The stock is trading close to its 52-week low and has fallen 59% over the last year. Separately, Grid Dynamics reported fourth-quarter 20…
Adam Crystal, President of Research & Development at Tango Therapeutics (NASDAQ: TNGX), sold 27,000 shares on April 1, 2026, in transactions tied to a pre-established Rule 10b5-1 plan. The sale followed the exercise of stock options and leaves Crystal with 112,622 shares. The company reported sizable 2025 losses, while several analysts reiterated o…
Hinge Health Executive Chairman and Co-Founder Gabriel M.I. Mecklenburg sold 50,000 shares of Class A Common Stock on April 1, 2026, in two tranches for roughly $1.9 million and converted 50,000 Class B shares to Class A that same day. The transaction occurred as the company, valued at $3.03 billion, traded near $38.98, and amid a slate of analyst …
Remitly Global Chief Business Officer Pankaj Sharma sold 10,000 shares on April 1, 2026, for about $152,600 and exercised options to buy 10,000 shares the same day. The company delivered quarterly revenue and adjusted EBITDA ahead of expectations and issued first-quarter fiscal 2026 guidance while updating its leadership team.
Klaviyo Co-CEO and director Andrew Bialecki sold 200,000 shares of Series A common stock on March 31, 2026, generating $3.88 million, and converted 200,000 Series B shares into Series A that same day. The transactions, executed under a Rule 10b5-1 plan adopted May 20, 2025, occur as Klaviyo announces a $500 million repurchase program that includes …
Walter Timothy Winn, Co-COO and EVP of Southland Holdings, Inc. (NASDAQ:SLND), bought 29,177 shares on March 31, 2026, in a transaction worth $42,890. The purchase occurred as the company contends with a large fourth-quarter loss for 2025 and a legal settlement tied to a major convention center expansion project. InvestingPro analysis flags SLND as…
Airgain Inc. President and CEO Suen Jacob sold 1,000 shares on April 1, 2026, under a Rule 10b5-1 plan, netting $5,510. The company reported Q4 2025 results that missed analyst expectations while disclosing new commercial wins and a strategic partnership aimed at expanding 4G and 5G coverage. Shares are trading near their assessed Fair Value and th…
Ionis Pharmaceuticals director Joseph Klein III executed sales of 22,321 shares on April 1, 2026, totaling about $1.69 million, while also exercising options that converted to 22,321 shares with an aggregate value of $880,706. The company simultaneously disclosed new wholesale pricing for Tryngolza and multiple firms adjusted or reaffirmed analyst …
Rubrik director John Wendell Thompson sold 13,500 Class A shares on April 1, 2026, for about $660,331 under a Rule 10b5-1 trading plan, including the conversion of 11,000 Class B shares to Class A. The company's stock has fallen 39% over six months even as Rubrik reported quarterly results and an outlook that topped FactSet consensus and launched s…
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals (IONS), disposed of 6,193 shares on April 2, 2026 under a Rule 10b5-1 plan, netting $458,613 at a weighted average price of $74.0535. The transaction coincides with a new wholesale acquisition cost for Tryngolza that exceeds earlier guidance and h…
Reddit Chief Executive Officer Steve Huffman sold 14,697 shares of Class A common stock on March 31, 2026, realizing roughly $2.39 million in proceeds. The sales followed an option exercise that added 18,000 shares at $25.29 per share. The transactions took place under a Rule 10b5-1 plan adopted in May 2025. Reddit recently reported strong fourth-q…
John W. Kozarich, a director of Ligand Pharmaceuticals Inc (LGND), sold 467 shares on April 1, 2026, for roughly $94,440 under a pre-arranged trading plan. The transaction comes amid strong quarterly results for Ligand and mixed valuation signals from market analytics and analysts alike. Following the trades Kozarich holds 42,253 shares.
V-Co Investors 3 LLC, a ten percent owner of Vivos Therapeutics, Inc. (VVOS), bought 1,353,625 shares of common stock for $1.34 per share on March 31, 2026, totaling $1,813,857. The investor also acquired multiple classes of warrants and pre-funded warrants, while the company completed an agreement to immediately exercise outstanding warrants at a …
Maria VG Woods, Executive Vice President - General Counsel at National CineMedia, sold 12,066 shares of common stock on April 1, 2026, at $3.04 per share for proceeds of $36,680. The transaction occurred as the stock trades near its 52-week low and after a recent vesting of restricted stock units. Separately, National CineMedia reported a 7.9% rise…
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 38,120 shares on April 1 and 2, 2026 for about $553,693 at weighted average prices between $14.45 and $14.60. On those same dates she exercised options to buy 29,444 shares at $7.27 for $214,057. The stock trades at $14.81, up 86.5% year over year. InvestingPro…
Zenas BioPharma director Lu Hongbo purchased 3,768 shares of the company's common stock on March 31, 2026, for $18.63 per share, a total of $70,197. The purchase occurred amid mixed market performance for the shares and a series of financing moves and clinical milestones, including positive Phase 2 data for obexelimab and recent public offerings an…
Accel Entertainment CEO Andrew H. Rubenstein sold 45,000 shares of Class A-1 common stock on April 1, 2026, for roughly $497,276. The company reported solid fourth-quarter 2025 results, marking its 13th consecutive quarter of beating estimates, and received an upward price-target revision from Citizens.
Ingredion Inc. director Jorge A. Uribe reported a small open-market sale of company shares and receipt of stock as annual director retainer. The filings show a fractional sale worth $83, issuance of 380 shares as compensation, tax-withholding of part of the retainer, and the insider's updated direct and indirect holdings. The disclosures arrive as …
Axcelis Technologies President and CEO Russell Low sold 1,244 shares on April 1, 2026, for $94.06 each, totaling $117,010. Low retains 132,282 shares, including 83,480 restricted stock units subject to forfeiture under the 2012 Equity Incentive Plan. The sale was carried out under a Rule 10b5-1 trading plan adopted December 11, 2025. Axcelis report…
CarGurus Chief People Officer Jennifer Ladd Hanson disclosed two recent stock dispositions totaling $128,980 tied to a prearranged trading plan and tax liabilities on vested restricted stock units. The transactions come while the shares trade below the year-to-date level and as analysts adjust forecasts and price targets following quarterly results…
EverQuote, Inc. NASDAQ:EVER Chief Financial Officer Joseph Sanborn sold 650 shares of Class A Common Stock on April 2, 2026, under a Rule 10b5-1 plan to satisfy tax liabilities from a restricted stock unit vesting. The sale coincides with shares trading near a 52-week low while InvestingPro's Fair Value assessment indicates the stock may be underva…
Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), sold 8,148 shares on April 2, 2026, for a total of $124,148 at a weighted average price of $15.2367. The sale - executed under a Rule 10b5-1 trading plan - leaves Ring with 26,453 shares. Nurix also amended an equity distribution agreement with Piper Sandler to permit up to $413.65 m…
Daphne Karydas, a member of Mineralys Therapeutics' board, sold 3,000 shares on March 31, 2026 for $75,000 and exercised options to acquire 3,000 shares at $12.02 the same day. The stock has gained strongly over the past year, while analysts differ on fair value amid progress toward a potential commercial launch of lorundrostat and a recent quarter…
Andrew Reardon, Chief Legal Officer and Secretary at Ligand Pharmaceuticals (LGND), sold nearly 5,000 shares on April 1, 2026 under a pre-arranged trading plan and exercised options to acquire 5,000 shares the same day. The transactions leave Reardon with a direct holding of 41,382 shares. The moves come as Ligand posted robust fourth-quarter and f…
